HomeAI · summaries
Storia in 12 fonti
Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide
South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO PolyPeptide for 1.46 billio | South Korean contract manufacturer Samsung Biologics has tapped into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO PolyPeptide for 1.46 billion Swiss francs ($1.8 billion).
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
asiabusinessoutlook.com
1.8B Deal Puts Samsung Biologics Ahead in CDMO Race
Samsung Biologics proposed acquisition marks a decisive move to consolidate its position as a global contract development and manufacturing organization
- ·
swissinfo.ch
Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal
(Bloomberg) -- Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion…
